This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
MetLife (MET) Unit Hits Milestone in Agricultural Mortgage Loans
by Zacks Equity Research
MetLife (MET) business unit MetLife Investment Management (MIM) creates a record by originating $6 billion in agricultural mortgage loans during 2021.
CME Group (CME) Unveils Micro-Sized Bitcoin and Ether Options
by Zacks Equity Research
CME Group (CME) introduces Micro Bitcoin and Micro Ether futures to add to the existing suite of cryptocurrency derivative offerings.
Should You Retain Prudential Financial (PRU) Stock Now?
by Zacks Equity Research
Prudential Financial (PRU) benefits from higher net investment spread and fee income, favorable underwriting results, and effective capital deployment.
Here's Why You Should Hold on to Argo Group (ARGO) Stock Now
by Zacks Equity Research
Argo Group's (ARGO) highly profitable businesses, exiting reinsurance operations and non-core lines of business, lowering property exposure substantially and reducing volatility bodes well for growth.
Here's Why You Should Hold on to Assurant (AIZ) Stock for Now
by Zacks Equity Research
Assurant (AIZ) is set to gain on solid segmental performance and sufficient liquidity.
Here's Why You Should Hold Hartford Financial (HIG) Stock
by Zacks Equity Research
Riding high on acquisitions and divestitures along with restructuring initiatives, Hartford Financial (HIG) has enough potential to reap benefits for investors.
Cigna Corp. (CI) Up 7.8% in 3 Months: More Room to Grow?
by Zacks Equity Research
Cigna Corp. (CI) expects to buy back more than $7 billion worth of shares in 2022.
Best Income Stocks to Buy for March 18th
by Zacks Equity Research
TTE, FISI, and HMN made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 18, 2022
Horace Mann (HMN) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Horace Mann (HMN) have what it takes? Let's find out.
MetLife (MET) Ties Up to Offer Better Pet Care With New Program
by Zacks Equity Research
MetLife (MET) collaborates with LifeBalance for launching MyPets rewards program in a bid to offer pet parents substantial savings while purchasing pet care commodities.
Here's Why You Should Hold EverQuote (EVER) in Your Portfolio
by Zacks Equity Research
EverQuote (EVER) is poised to benefit from strategic acquisitions, improved guidance and sufficient liquidity.
Why Should You Add Horace Mann (HMN) Stock to Your Portfolio?
by Zacks Equity Research
Focus on improving product offerings, strengthening distribution, and modernizing infrastructure bode well for Horace Mann Educators (HMN).
Old Republic (ORI) Rises 15% in a Year: More Upside Left?
by Zacks Equity Research
Solid market presence, niche focus, low property catastrophe exposure at its General Insurance segment and solid capital position continue to drive Old Republic (ORI).
Brown & Brown (BRO) Up 35% in a Year: More Upside Left?
by Zacks Equity Research
Strong performing segments, strategic buyouts to capitalize on growing markets opportunities, sturdy financial standing and effective capital deployment continue to drive Brown & Brown (BRO).
Reasons Why Investors Should Retain Radian Group (RDN) Stock
by Zacks Equity Research
Radian Group (RDN) is poised to grow due to growth in the purchase market, lower refinance activity as well as financial flexibility.
Reasons Why You Should Retain MGIC Investment (MTG) Stock
by Zacks Equity Research
MGIC Investment (MTG) is poised to grow due to lower ceded premiums written, a decreasing delinquency rate, a lower leverage ratio and effective capital deployment.
MetLife's (MET) Structured Solution to Offer Financial Security
by Zacks Equity Research
MetLife (MET) launches a Structured Installment Sale solution with an aim to offer a guaranteed periodic income and defer tax liability of the sellers of qualified properties.
Horace Mann (HMN) to Share More Profits, Raises Dividend
by Zacks Equity Research
Horace Mann's (HMN) recent dividend hike reflects solid financial foundation and operational performance.
Best Income Stocks to Buy for March 8th
by Zacks Equity Research
HMN, BAK, and LCNB made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 8, 2022.
Zacks.com featured highlights include Meridian Bioscience, Innoviva, Horace Mann Educators and Maravai LifeSciences
by Zacks Equity Research
Meridian Bioscience, Innoviva, Horace Mann Educators and Maravai LifeSciences are included in this blog.
Hartford Financial's (HIG) New Product Expands Coverage
by Zacks Equity Research
Hartford Financial (HIG) introduces a critical illness insurance product covering over 160 health conditions and offers benefits to employees depending on the intensity of disease.
Sail Through the Choppy Market With These 4 Low-Beta Stocks
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Meridian (VIVO), Innoviva (INVA), Horace (HMN) and Maravai LifeSciences (MRVI) are well poised to gain.
Aflac (AFL) Ties Up to Cater to Employees' Mental Health Issues
by Zacks Equity Research
Aflac (AFL) teams up with NeuroFlow for integrating a mental health solution into AFL's Group Long-Term Disability offering, thereby aiming to address employees' behavioral health challenges.
After Golden Cross, Horace Mann (HMN)'s Technical Outlook is Bright
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
Prudential Financial (PRU) Up 27.3% in a Year: More Room to Run?
by Zacks Equity Research
Prudential Financial (PRU) stock soars on the back of higher variable investment income, cost savings initiatives and effective capital deployment.